for at udvide
kategorilisten.
Søgning på underkategorier- og emner:
Bemærk: Kan ikke leveres før jul.
Providing analysis of the thermal comfort assessment of clothing as the basis for developing standards, this book discusses the thermal... Læs mere
Bemærk: Kan ikke leveres før jul.
Providing analysis of the thermal comfort assessment of clothing as the basis for developing standards, this book discusses the thermal... Læs mere
Bemærk: Kan ikke leveres før jul.
Bemærk: Kan ikke leveres før jul.
Georgian Dublin is synonymous with a period of unprecedented expansion in the market for luxury goods. This book considers the demand for silver goods... Læs mere
Bemærk: Kan ikke leveres før jul.
First published in 1990, this book provides an overview of the global distribution of the electronics industry and the structural factors which promoted this distribution by the end of the 1980s.
Bemærk: Kan ikke leveres før jul.
First published in 1955, this book offers a detailed history from the past to the mid-20th century on economic control.
Bemærk: Kan ikke leveres før jul.
This book provides the reader with a domain-independent method for reducing risk through maximizing reliability, reducing epistemic... Læs mere
Bemærk: Kan ikke leveres før jul.
Risk and Food Safety in China and Japan reframes the relationship between risk and food. This book will be an... Læs mere
Bemærk: Kan ikke leveres før jul.
This book documents the long and still ongoing battle between the US Food and Drug Administration (FDA) and the dietary supplement industry.... Læs mere
Bemærk: Kan ikke leveres før jul.
This book documents the long and still ongoing battle between the US Food and Drug Administration (FDA) and the dietary supplement industry.... Læs mere
Bemærk: Kan ikke leveres før jul.
Over the last 50 years, the theory and the methods of reliability analysis have developed significantly. Therefore it is very important to the... Læs mere
Bemærk: Kan ikke leveres før jul.
The 80-80 Rule sets the standard for redefining innovation as a platform to reignite the growth engines of the biopharmaceutical industry, which should become the new normal.